Definium Therapeutics (DFTX) Total Current Liabilities (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Total Current Liabilities data on file, last reported at $81.1 million in Q1 2026.

• Quarterly Total Current Liabilities rose 166.11% year-over-year to $81.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.1 million (up 166.11% YoY) and the FY2025 annual result came in at $66.7 million, up 71.69% from the prior year.
• Total Current Liabilities rose to $81.1 million in Q1 2026 per DFTX's latest filing, from $66.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $81.1 million in Q1 2026 and bottomed at $7.9 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $33.3 million (2024), against an average of $38.0 million.
• The widest annual swing landed in 2023, when Total Current Liabilities soared 346.21%; it then tumbled 53.3% in 2025.
• Tracing DFTX's Total Current Liabilities over 5 years: stood at $17.9 million in 2022, then surged by 80.23% to $32.2 million in 2023, then rose by 20.48% to $38.8 million in 2024, then soared by 71.69% to $66.7 million in 2025, then climbed by 21.61% to $81.1 million in 2026.
• Per Business Quant, the three latest DFTX Total Current Liabilities figures stand at $81.1 million (Q1 2026), $66.7 million (Q4 2025), and $65.4 million (Q3 2025).

Peer Comparison